Lynn Seely, Myovant CEO (Myovant)
December 18, 2020 04:11 PM ESTUpdated December 21, 12:30 PM
FDA+

In ground­break­ing move, FDA ap­proves My­ovan­t's re­l­u­golix as the first once-a-day pill for ad­vanced prostate can­cer

Max Gelman

Senior Editor

My­ovant Sci­ences $MY­OV won’t be get­ting coal in their stock­ing this Christ­mas.

The Swiss biotech, for­mer­ly part of the Vivek Ra­maswamy fam­i­ly of Vants, …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Sanofi to pay $125M up­front for two im­munol­o­gy drugs from lit­tle-known biotech

US drugs re­ly heav­i­ly on in­gre­di­ents made over­seas, new re­port shows

Sarep­ta los­es CMO to RNA edit­ing up­start; An­oth­er wave of per­son­nel moves at Dyne

Biotech seed rounds sink to low­est lev­el in years as in­dus­try slump drags on

Ex­clu­sive: VelaV­i­go inks an­oth­er US biotech deal as Chi­na drug de­vel­op­ment scene booms

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times